S&P 500   4,586.07 (+0.81%)
DOW   36,143.40 (+0.25%)
QQQ   390.37 (+1.38%)
AAPL   194.30 (+1.03%)
MSFT   370.30 (+0.41%)
META   326.81 (+2.95%)
GOOGL   136.95 (+5.33%)
AMZN   147.00 (+1.72%)
TSLA   241.22 (+0.77%)
NVDA   463.94 (+1.96%)
NIO   7.56 (-2.45%)
BABA   72.25 (+1.06%)
AMD   126.94 (+8.66%)
T   17.10 (+0.94%)
F   10.84 (+1.40%)
MU   73.73 (+0.82%)
CGC   0.73 (+4.63%)
GE   118.62 (-0.99%)
DIS   92.72 (+1.33%)
AMC   6.88 (+1.33%)
PFE   28.85 (+0.21%)
PYPL   58.78 (-1.26%)
XOM   98.58 (-0.53%)
S&P 500   4,586.07 (+0.81%)
DOW   36,143.40 (+0.25%)
QQQ   390.37 (+1.38%)
AAPL   194.30 (+1.03%)
MSFT   370.30 (+0.41%)
META   326.81 (+2.95%)
GOOGL   136.95 (+5.33%)
AMZN   147.00 (+1.72%)
TSLA   241.22 (+0.77%)
NVDA   463.94 (+1.96%)
NIO   7.56 (-2.45%)
BABA   72.25 (+1.06%)
AMD   126.94 (+8.66%)
T   17.10 (+0.94%)
F   10.84 (+1.40%)
MU   73.73 (+0.82%)
CGC   0.73 (+4.63%)
GE   118.62 (-0.99%)
DIS   92.72 (+1.33%)
AMC   6.88 (+1.33%)
PFE   28.85 (+0.21%)
PYPL   58.78 (-1.26%)
XOM   98.58 (-0.53%)
S&P 500   4,586.07 (+0.81%)
DOW   36,143.40 (+0.25%)
QQQ   390.37 (+1.38%)
AAPL   194.30 (+1.03%)
MSFT   370.30 (+0.41%)
META   326.81 (+2.95%)
GOOGL   136.95 (+5.33%)
AMZN   147.00 (+1.72%)
TSLA   241.22 (+0.77%)
NVDA   463.94 (+1.96%)
NIO   7.56 (-2.45%)
BABA   72.25 (+1.06%)
AMD   126.94 (+8.66%)
T   17.10 (+0.94%)
F   10.84 (+1.40%)
MU   73.73 (+0.82%)
CGC   0.73 (+4.63%)
GE   118.62 (-0.99%)
DIS   92.72 (+1.33%)
AMC   6.88 (+1.33%)
PFE   28.85 (+0.21%)
PYPL   58.78 (-1.26%)
XOM   98.58 (-0.53%)
S&P 500   4,586.07 (+0.81%)
DOW   36,143.40 (+0.25%)
QQQ   390.37 (+1.38%)
AAPL   194.30 (+1.03%)
MSFT   370.30 (+0.41%)
META   326.81 (+2.95%)
GOOGL   136.95 (+5.33%)
AMZN   147.00 (+1.72%)
TSLA   241.22 (+0.77%)
NVDA   463.94 (+1.96%)
NIO   7.56 (-2.45%)
BABA   72.25 (+1.06%)
AMD   126.94 (+8.66%)
T   17.10 (+0.94%)
F   10.84 (+1.40%)
MU   73.73 (+0.82%)
CGC   0.73 (+4.63%)
GE   118.62 (-0.99%)
DIS   92.72 (+1.33%)
AMC   6.88 (+1.33%)
PFE   28.85 (+0.21%)
PYPL   58.78 (-1.26%)
XOM   98.58 (-0.53%)

Scilex Stock Price, News & Analysis (NASDAQ:SCLX)

$1.16
+0.02 (+1.75%)
(As of 01:57 PM ET)
Compare
Today's Range
$1.12
$1.18
50-Day Range
$0.95
$2.23
52-Week Range
$0.90
$16.90
Volume
172,080 shs
Average Volume
694,271 shs
Market Capitalization
$180.89 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.00

Scilex MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
589.7% Upside
$8.00 Price Target
Short Interest
Bearish
5.66% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.08mentions of Scilex in the last 14 days
Based on 9 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.95) to ($0.53) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.84 out of 5 stars

Medical Sector

606th out of 958 stocks

Biological Products, Except Diagnostic Industry

85th out of 145 stocks


SCLX stock logo

About Scilex Stock (NASDAQ:SCLX)

Scilex Holding Company, a biopharmaceutical company, focuses on acquiring, developing, and commercializing non-opioid management products for the treatment of acute and chronic pain. It offers ZTlido, a prescription lidocaine topical product for the relief of neuropathic pain related with postherpetic neuralgia, which is a form of post-shingles nerve pain. The company also develops SP-102, a viscous gel formulation of corticosteroid for epidural injections that is in a Phase III clinical trial to treat lumbosacral radicular pain; SP-103, which is in Phase II clinical trial for the treatment of low back pain; and SP-104 (4.5 mg), a novel low-dose delayed-release naltrexone hydrochloride formulation that has completed Phase I clinical trial for the treatment of fibromyalgia. The company is headquartered in Palo Alto, California. Scilex Holding Company is a subsidiary of Sorrento Therapeutics, Inc.

SCLX Stock Price History

SCLX Stock News Headlines

New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Scilex (NASDAQ:SCLX) Receives "Buy" Rating from HC Wainwright
New CBOE “special perk” helps traders target income every weekend
You might not immediately realize what you’re reading. Let me help you out a little… What you're looking at is a “special perk” set up by the Chicago Board of Options Exchange.
Scilex Holding Co SCLX
SCLX Provides non-Opioid Pain Relief
SCLX: An Innovative and Growing Pain Management Company
Scilex (NASDAQ: SCLX)
Why Shares of Scilex Are Up Monday
See More Headlines
Receive SCLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Scilex and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Today
12/07/2023
Fiscal Year End
12/31/2023
Next Earnings (Estimated)
2/13/2024

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:SCLX
Fax
N/A
Employees
109
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.00
High Stock Price Target
$12.00
Low Stock Price Target
$4.00
Potential Upside/Downside
+583.8%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-23,360,000.00
Net Margins
-245.17%
Pretax Margin
-245.07%

Debt

Sales & Book Value

Annual Sales
$45.20 million
Book Value
$0.26 per share

Miscellaneous

Free Float
142,844,000
Market Cap
$182.45 million
Optionable
Not Optionable
Beta
0.32
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Henry H. Ji Ph.D. (Age 59)
    Executive Chairman
    Comp: $4.35M
  • Mr. Jaisim Shah (Age 63)
    President, CEO & Director
    Comp: $785.73k
  • Mr. Stephen Ma (Age 51)
    Senior VP & CFO
  • Dr. Suketu D. Desai Ph.D. (Age 57)
    Chief Technical Officer & Senior VP
  • Mr. Steven F. Lincoln J.D.
    General Counsel & Chief Compliance Officer
  • Mr. Suresh K. Khemani (Age 63)
    Senior VP & Chief Commercial Officer
    Comp: $456.82k
  • Dr. Dmitri V. Lissin M.D. (Age 63)
    Senior VP & Chief Medical Officer
    Comp: $528.83k














SCLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Scilex stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Scilex in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" SCLX shares.
View SCLX analyst ratings
or view top-rated stocks.

What is Scilex's stock price target for 2024?

2 equities research analysts have issued 12 month price targets for Scilex's shares. Their SCLX share price targets range from $4.00 to $12.00. On average, they expect the company's share price to reach $8.00 in the next twelve months. This suggests a possible upside of 589.7% from the stock's current price.
View analysts price targets for SCLX
or view top-rated stocks among Wall Street analysts.

How have SCLX shares performed in 2023?

Scilex's stock was trading at $3.99 at the beginning of 2023. Since then, SCLX stock has decreased by 70.9% and is now trading at $1.16.
View the best growth stocks for 2023 here
.

When is Scilex's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, February 13th 2024.
View our SCLX earnings forecast
.

Who are Scilex's major shareholders?

Scilex's stock is owned by a number of institutional and retail investors. Top institutional investors include Northern Trust Corp (0.45%), Hudson Bay Capital Management LP (0.30%), Tower Research Capital LLC TRC (0.08%), K2 Principal Fund L.P. (0.00%), Bank of New York Mellon Corp (0.03%) and Donald L. Hagan LLC (0.02%).

How do I buy shares of Scilex?

Shares of SCLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:SCLX) was last updated on 12/7/2023 by MarketBeat.com Staff

My Account -